Aug. 19 at 10:07 AM
$AKBA DAVITA PRIMED TO TRANSITION TO VAFSEO IN CLINICS - (1)Aug. 4, ‘25, Akebia initiated Vafseo post marketing study in conjunction w/ Davita. VOCAL, an open label active controlled study, is being conducted at dialysis clinics to evaluate efficacy & safety of treating patients w/ Vafseo 3Xs a week cf SOC ESA; (2)Nov. 10, ‘25, Akebia expects Davita’s operational pilot of Vafseo initiated at over 100 clinics to complete in Nov. ‘26, at which point Vafseo is to be widely available to Davita’s 275,000 patients; (3)Aug. 5, ‘26, Akebia & Davita, “high level of interaction.” Davita studying VOICE results. Heightened level of Davita senior clinical team engagement regarding detailed operational implementation. Davita physicians ATH in awareness of Vafseo, w/ a likelihood to recommend Vafseo, & in their preference to use Vafseo instead of ESA to improve efficacy. There’s pent up desire to use Vafseo in Davita. In very beginning of June, Davita rolled out their village wide 3Xs weekly dosing.
